Evotec SE (EVO)
USD 4.33
(-9.41%)
USD 4.33
(-9.41%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.17 Billion EUR | 10.19% |
| 2022 | 1.07 Billion EUR | 24.79% |
| 2021 | 857.47 Million EUR | 15.87% |
| 2020 | 740.04 Million EUR | 5.14% |
| 2019 | 703.88 Million EUR | 102.85% |
| 2018 | 347 Million EUR | 3.42% |
| 2017 | 335.52 Million EUR | 144.14% |
| 2016 | 137.43 Million EUR | 35.47% |
| 2015 | 101.44 Million EUR | 53.2% |
| 2014 | 66.21 Million EUR | -3.21% |
| 2013 | 68.41 Million EUR | -6.13% |
| 2012 | 72.88 Million EUR | 2.69% |
| 2011 | 70.96 Million EUR | 19.83% |
| 2010 | 59.22 Million EUR | 68.67% |
| 2009 | 35.11 Million EUR | 6.27% |
| 2008 | 33.04 Million EUR | -11.48% |
| 2007 | 37.32 Million EUR | -45.39% |
| 2006 | 68.35 Million EUR | 82.55% |
| 2005 | 37.44 Million EUR | 307.75% |
| 2004 | 9.18 Million EUR | 61.18% |
| 2003 | 5.69 Million EUR | 0.0% |
| 2002 | - EUR | 0.0% |
| 2001 | - EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 987.42 Million EUR | -10.41% |
| 2024 Q1 | 1.1 Billion EUR | -6.53% |
| 2023 FY | 1.17 Billion EUR | 10.19% |
| 2023 Q2 | 1.12 Billion EUR | 0.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q3 | 1.11 Billion EUR | -1.18% |
| 2023 Q4 | 1.17 Billion EUR | 5.88% |
| 2022 Q4 | 1.07 Billion USD | 3.47% |
| 2022 Q3 | 1.03 Billion EUR | 1.57% |
| 2022 Q2 | 1.01 Billion EUR | 16.34% |
| 2022 Q1 | 875.16 Million EUR | 2.06% |
| 2022 FY | 1.07 Billion EUR | 24.79% |
| 2021 Q4 | 857.47 Million EUR | 10.62% |
| 2021 FY | 857.47 Million EUR | 15.87% |
| 2021 Q2 | 768.54 Million EUR | -2.43% |
| 2021 Q1 | 787.66 Million EUR | 6.43% |
| 2021 Q3 | 775.17 Million EUR | 0.86% |
| 2020 Q2 | 714.59 Million EUR | 2.95% |
| 2020 Q1 | 694.09 Million EUR | -1.39% |
| 2020 Q4 | 740.04 Million EUR | 6.19% |
| 2020 Q3 | 696.89 Million EUR | -2.48% |
| 2020 FY | 740.04 Million EUR | 5.14% |
| 2019 FY | 703.88 Million EUR | 102.85% |
| 2019 Q4 | 703.88 Million EUR | 13.29% |
| 2019 Q3 | 621.29 Million EUR | -1.14% |
| 2019 Q1 | 432.56 Million EUR | 24.66% |
| 2019 Q2 | 628.47 Million EUR | 45.29% |
| 2018 Q4 | 347 Million EUR | -8.7% |
| 2018 Q2 | 340.7 Million EUR | 4.51% |
| 2018 FY | 347 Million EUR | 3.42% |
| 2018 Q1 | 326.01 Million EUR | -2.83% |
| 2018 Q3 | 380.08 Million EUR | 11.56% |
| 2017 Q2 | 107.27 Million EUR | 1.76% |
| 2017 Q1 | 105.41 Million EUR | -23.29% |
| 2017 FY | 335.52 Million EUR | 144.14% |
| 2017 Q4 | 335.52 Million EUR | 3.01% |
| 2017 Q3 | 325.72 Million EUR | 203.65% |
| 2016 Q1 | 92.28 Million EUR | -9.03% |
| 2016 FY | 137.43 Million EUR | 35.47% |
| 2016 Q4 | 137.43 Million EUR | 66.89% |
| 2016 Q3 | 82.35 Million EUR | -3.57% |
| 2016 Q2 | 85.39 Million EUR | -7.47% |
| 2015 Q1 | 64.67 Million EUR | -2.34% |
| 2015 FY | 101.44 Million EUR | 53.2% |
| 2015 Q3 | 107.1 Million EUR | -2.74% |
| 2015 Q4 | 101.44 Million EUR | -5.29% |
| 2015 Q2 | 110.12 Million EUR | 70.29% |
| 2014 Q1 | 63.66 Million EUR | -6.94% |
| 2014 FY | 66.21 Million EUR | -3.21% |
| 2014 Q4 | 66.21 Million EUR | 14.11% |
| 2014 Q3 | 58.02 Million EUR | -8.91% |
| 2014 Q2 | 63.7 Million EUR | 0.07% |
| 2013 Q1 | 72.52 Million EUR | -0.49% |
| 2013 Q4 | 68.41 Million EUR | 0.33% |
| 2013 FY | 68.41 Million EUR | -6.13% |
| 2013 Q3 | 68.18 Million EUR | -2.43% |
| 2013 Q2 | 69.88 Million EUR | -3.64% |
| 2012 Q4 | 72.88 Million EUR | 5.4% |
| 2012 Q1 | 69.02 Million EUR | -2.73% |
| 2012 Q2 | 64.37 Million EUR | -6.75% |
| 2012 Q3 | 69.14 Million EUR | 7.42% |
| 2012 FY | 72.88 Million EUR | 2.69% |
| 2011 Q3 | 63.71 Million EUR | 2.69% |
| 2011 Q4 | 70.96 Million EUR | 11.39% |
| 2011 Q1 | 56.46 Million EUR | -4.65% |
| 2011 Q2 | 62.04 Million EUR | 9.87% |
| 2011 FY | 70.96 Million EUR | 19.83% |
| 2010 Q4 | 59.22 Million EUR | 29.72% |
| 2010 FY | 59.22 Million EUR | 68.67% |
| 2010 Q3 | 45.65 Million EUR | 42.2% |
| 2010 Q2 | 32.1 Million EUR | 2.51% |
| 2010 Q1 | 31.32 Million EUR | -10.8% |
| 2009 Q4 | 35.11 Million EUR | 5.45% |
| 2009 Q1 | 39.44 Million EUR | 19.37% |
| 2009 Q2 | 33.74 Million EUR | -14.43% |
| 2009 Q3 | 33.29 Million EUR | -1.34% |
| 2009 FY | 35.11 Million EUR | 6.27% |
| 2008 Q2 | 34.45 Million EUR | 15.85% |
| 2008 Q4 | 33.04 Million EUR | 7.34% |
| 2008 Q3 | 30.78 Million EUR | -10.66% |
| 2008 FY | 33.04 Million EUR | -11.48% |
| 2008 Q1 | 29.74 Million USD | 322.8% |
| 2007 FY | 37.32 Million EUR | -45.39% |
| 2007 Q3 | 36.97 Million EUR | 0.0% |
| 2007 Q4 | 7.03 Million EUR | -80.97% |
| 2006 Q3 | 11.76 Million EUR | 5.67% |
| 2006 Q2 | 11.12 Million EUR | -6.36% |
| 2006 Q4 | 71.17 Million EUR | 505.18% |
| 2006 FY | 68.35 Million EUR | 82.55% |
| 2006 Q1 | 11.88 Million EUR | -3.25% |
| 2005 FY | 37.44 Million EUR | 307.75% |
| 2005 Q2 | 8.23 Million EUR | -2.33% |
| 2005 Q1 | 8.43 Million EUR | -8.18% |
| 2005 Q4 | 12.28 Million EUR | 0.0% |
| 2004 Q1 | 8.1 Million EUR | 42.31% |
| 2004 FY | 9.18 Million EUR | 61.18% |
| 2004 Q4 | 9.18 Million EUR | 0.0% |
| 2004 Q2 | 8.15 Million EUR | 0.53% |
| 2003 FY | 5.69 Million EUR | 0.0% |
| 2003 Q4 | 5.69 Million EUR | 0.0% |
| 2002 FY | - EUR | 0.0% |
| 2001 FY | - EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -2145.297% |
| Harrow Health, Inc. | 241.75 Million USD | -387.748% |
| Dynavax Technologies Corporation | 375.02 Million USD | -214.419% |
| Biofrontera Inc. | 23.13 Million USD | -4995.92% |
| DURECT Corporation | 30.4 Million USD | -3778.001% |
| Cronos Group Inc. | 43.73 Million USD | -2596.046% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | -44.261% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -2333.987% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -5520.831% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -31159.361% |
| Radius Health, Inc. | 804.29 Million USD | -46.607% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -8472.9% |
| ProPhase Labs, Inc. | 42.54 Million USD | -2671.589% |
| Phibro Animal Health Corporation | 725.54 Million USD | -62.519% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -12721.517% |
| Procaps Group S.A. | 462.06 Million USD | -155.19% |
| Alvotech | 1.88 Billion USD | 37.366% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -8309.25% |
| Rockwell Medical, Inc. | 30.88 Million USD | -3718.227% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -19105.567% |
| Alpha Teknova, Inc. | 38.55 Million USD | -2958.663% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | -761.501% |
| SCYNEXIS, Inc. | 55.45 Million USD | -2026.501% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -1204.667% |
| Theratechnologies Inc. | 98.63 Million USD | -1095.415% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | -149.992% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -13366.709% |
| Safety Shot Inc | 3.89 Million USD | -30196.292% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -141.895% |
| SIGA Technologies, Inc. | 57.97 Million USD | -1933.805% |
| Tilray Brands, Inc. | 892.11 Million USD | -32.174% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | -436.463% |
| Viatris Inc. | 27.21 Billion USD | 95.668% |
| PetIQ, Inc. | 645.22 Million USD | -82.749% |
| OptiNose, Inc. | 194.33 Million USD | -506.759% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | -15.67% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -19105.567% |
| Organogenesis Holdings Inc. | 181.36 Million USD | -550.161% |
| Alimera Sciences, Inc. | 107.35 Million USD | -998.371% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | -24.399% |
| Silver Spike Investment Corp. | 3 Million USD | -39076.452% |
| Assertio Holdings, Inc. | 148.41 Million USD | -694.486% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -62092.34% |
| Cosmos Health Inc. | 30.25 Million USD | -3797.675% |
| Journey Medical Corporation | 56.49 Million USD | -1987.019% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -5431.796% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -16682.593% |
| Embecta Corp. | 2.03 Billion USD | 42.088% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -537066.533% |
| Procaps Group, S.A. | 462.06 Million USD | -155.19% |
| PainReform Ltd. | 2.69 Million USD | -43718.097% |
| Incannex Healthcare Limited | 5.83 Million USD | -20125.472% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -13787.765% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | -580.065% |
| Shineco, Inc. | 47.6 Million USD | -2377.108% |
| Talphera, Inc. | 6.29 Million USD | -18646.343% |
| Pacira BioSciences, Inc. | 704.25 Million USD | -67.431% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | -619.408% |
| Alvotech | 1.88 Billion USD | 37.366% |
| Hempacco Co., Inc. | 18.82 Million USD | -6164.582% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | -583.166% |
| Lantheus Holdings, Inc. | 835.25 Million USD | -41.172% |
| Bright Green Corporation | 6.43 Million USD | -18215.103% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -78.445% |
| Kamada Ltd. | 109.96 Million USD | -972.259% |
| Indivior PLC | 1.95 Billion USD | 39.569% |
| Evoke Pharma, Inc. | 9.64 Million USD | -12121.547% |
| Flora Growth Corp. | 17.22 Million USD | -6746.737% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -13787.765% |
| Evolus, Inc. | 209.68 Million USD | -462.336% |
| HUTCHMED (China) Limited | 536.38 Million USD | -119.831% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | -34.992% |
| Akanda Corp. | 12.66 Million USD | -9207.409% |